Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733203 | 0.73 | ALDH1A1 (0.40) | MAPTHSD17B10MEN1KMT2AGAA | |
| SCHEMBL10537515 | 0.72 | TSHR (0.42) | MAPTHSD17B10MEN1KMT2AGAA | |
| SCHEMBL10537510 | 0.72 | TSHR (0.42) | MAPTHSD17B10MEN1KMT2AGAA | |
| SCHEMBL24740152 | 0.69 | MAPT (0.40) | MAPTHSD17B10MEN1KMT2AGAA | |
| SCHEMBL13888697 | 0.68 | ALDH1A1 (0.36) | MAPTALDH1A1LMNA | |
| SCHEMBL18618726 | 0.68 | MAPT (0.39) | MAPTHSD17B10MEN1KMT2AGAA | |
| SCHEMBL7986120 | 0.68 | BIRC2 (0.48) | MAPTHSD17B10ALDH1A1CA12CA14 | |
| SCHEMBL20906631 | 0.68 | TSHR (0.54) | MAPTHSD17B10MEN1KMT2AGAA | |
| SCHEMBL20906634 | 0.68 | TSHR (0.54) | MAPTHSD17B10MEN1KMT2AGAA | |
| SCHEMBL1274030 | 0.68 | TSHR (0.42) | MAPTHSD17B10MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027144-B1 | MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | MSD ITALIA SRL (IT) | 2015-04-29 | — | — | EP | disclosed |
| US-8178520-B2 | Macrocyclic compounds as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2012-05-15 | — | — | US | disclosed |
| US-20090258891-A1 | Macrocyclic Compounds As Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258891-A1 | Macrocyclic Compounds As Antiviral Agents | ZC3HAV1, HAVCR2, ZC3HAV1L | MAPT 4036/4885HSD17B10 3233/4885MEN1 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.